AZITRA INC (AZTR) Stock Price & Overview

NYSEARCA:AZTR • US05479L3024

Current stock price

0.2828 USD
+0.11 (+60.59%)
At close:
0.2517 USD
-0.03 (-11%)
After Hours:

The current stock price of AZTR is 0.2828 USD. Today AZTR is up by 60.59%. In the past month the price increased by 68.74%. In the past year, price decreased by -87.14%.

AZTR Key Statistics

52-Week Range0.1 - 2.664
Current AZTR stock price positioned within its 52-week range.
1-Month Range0.1 - 0.3799
Current AZTR stock price positioned within its 1-month range.
Market Cap
4.579M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-2.25
Dividend Yield
N/A

AZTR Stock Performance

Today
+60.59%
1 Week
+65.38%
1 Month
+68.74%
3 Months
-3.84%
Longer-term
6 Months -62.64%
1 Year -87.14%
2 Years -99.31%
3 Years N/A
5 Years N/A
10 Years N/A

AZTR Stock Chart

AZITRA INC / AZTR Daily stock chart

AZTR Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to AZTR. When comparing the yearly performance of all stocks, AZTR is a bad performer in the overall market: 93.43% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

AZTR Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to AZTR. AZTR has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AZTR Earnings

Next Earnings DateN/A
Last Earnings DateFeb 27, 2026
PeriodQ4 / 2025
EPS Reported-$0.20
Revenue Reported
EPS Surprise 38.46%
Revenue Surprise %

AZTR Forecast & Estimates

7 analysts have analysed AZTR and the average price target is 2.75 USD. This implies a price increase of 873.83% is expected in the next year compared to the current price of 0.2828.


Analysts
Analysts82.86
Price Target2.75 (872.42%)
EPS Next Y99.17%
Revenue Next YearN/A

AZTR Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

AZTR Financial Highlights

Over the last trailing twelve months AZTR reported a non-GAAP Earnings per Share(EPS) of -2.25. The EPS increased by 85.76% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-10.96M
Industry RankSector Rank
PM (TTM) N/A
ROA -218%
ROE -288.21%
Debt/Equity 0.05
Chartmill High Growth Momentum
EPS Q2Q%95.14%
Sales Q2Q%N/A
EPS 1Y (TTM)85.76%
Revenue 1Y (TTM)-100%

AZTR Ownership

Ownership
Inst Owners2.1%
Shares16.19M
Float15.64M
Ins Owners0.03%
Short Float %0.79%
Short Ratio0.07

About AZTR

Company Profile

AZTR logo image Azitra, Inc. is an early-stage clinical biopharmaceutical company, which engages in the development of therapeutic use in dermatology. The company is headquartered in Branford, Connecticut and currently employs 13 full-time employees. The company went IPO on 2023-06-16. The firm is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.

Company Info

IPO: 2023-06-16

AZITRA INC

21 Business Park Drive, Suite 6

Branford CONNECTICUT US

Employees: 13

AZTR Company Website

Phone: 12034890183

AZITRA INC / AZTR FAQ

What does AZITRA INC do?

Azitra, Inc. is an early-stage clinical biopharmaceutical company, which engages in the development of therapeutic use in dermatology. The company is headquartered in Branford, Connecticut and currently employs 13 full-time employees. The company went IPO on 2023-06-16. The firm is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.


What is the current price of AZTR stock?

The current stock price of AZTR is 0.2828 USD. The price increased by 60.59% in the last trading session.


What is the dividend status of AZITRA INC?

AZTR does not pay a dividend.


What is the ChartMill technical and fundamental rating of AZTR stock?

AZTR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Would investing in AZITRA INC be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AZTR.


What is the employee count for AZTR stock?

AZITRA INC (AZTR) currently has 13 employees.


What is the Short Interest ratio of AZITRA INC (AZTR) stock?

The outstanding short interest for AZITRA INC (AZTR) is 0.79% of its float.